Small, intimate and participant-led discussions tackling digital health challenges. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.
Digital health’s interaction with pharma is evolving; it has to evolve. Digital innovation around and beyond the molecule has yet to demonstrate real value, ROI and scale. While digital health found refuge with pharma initially, market observers are now questioning whether pharma should lead this digital charge or simply be a main consumer.
Digital will be a part of pharma’s future, as consumers demand the digital convenience they now take for granted in other industries. Pharma is learning from the past and focusing their efforts into high-potential initiatives.
Our recent HealthXL report maps out the next phase for digital health in pharma. Leading experts from across our community have shared their thoughts on driving innovation in and for the pharmaceutical industry to understand what has happened to digital health in pharma and how it’s evolving.
Join us in this roundtable to discuss the highlights from the report and how pharma can do digital health better in the next few years.
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.